🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Oesophageal Squamous Cell Carcinoma

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347NA1 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: anlotinib+bevacizumab VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma NCT06476067n/a2 sites📍 Nagoya📍 Chūō City of Hope Medical Center · Tests: Surgery Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors NCT07814248Phase 13 sites📍 Maumee📍 Portland📍 Fairfax TwoStep Therapeutics, Inc. · Tests: TS-104 Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893NA2 sites📍 San Francisco📍 Walnut Creek University of California, San Francisco · Tests: Radiation Therapy (RT) Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer NCT07016724Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: cadonilizumab combined with neoadjuvant radiochemotherapy, neoadjuvant radiochemotherapy Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma NCT06563869Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: PEG-rhG-GSF Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site📍 Shanghai Fudan University · Tests: Vebrekotuzumab, PD-1 antibody Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site📍 Zunyi Second Affiliated Hospital of Zunyi Medical University · Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Con… Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC NCT07177794Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: toripalimab, capecitabine Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726Phase 21 site📍 Chengdu Sichuan University · Tests: Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel, Cisplatin Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurre… Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites📍 Los Angeles📍 Baltimore📍 New York AstraZeneca · Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma NCT07266363n/a1 site📍 Monrovia City of Hope Medical Center · Tests: Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based val… A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites📍 Scottsdale📍 Fullerton📍 Los Angeles Alentis Therapeutics AG · Tests: ALE.P02, Pembrolizumab Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） NCT06509568Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724Phase 21 site📍 Beijing Shanghai Junshi Bioscience Co., Ltd. · Tests: JS212, JS001, 5-FU Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma NCT05833594n/a1 site📍 Hefei Anhui Provincial Hospital · Tests: Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: adebrelimab Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Tegafur A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma NCT06869213Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy